Ono Pharmaceutical (OTCMKTS:OPHLF) Sees Unusually-High Trading Volume After Analyst Upgrade

Ono Pharmaceutical Co. (OTCMKTS:OPHLF) saw an uptick in trading volume on Tuesday after Zacks Research upgraded the stock from a hold rating to a strong-buy rating. 1,086 shares were traded during mid-day trading, an increase of 199% from the previous session’s volume of 363 shares.The stock last traded at $15.63 and had previously closed at $14.90.

Ono Pharmaceutical Price Performance

The stock has a fifty day moving average of $14.42 and a 200-day moving average of $14.69. The company has a quick ratio of 2.56, a current ratio of 3.02 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $7.31 billion, a price-to-earnings ratio of 15.72 and a beta of 0.34.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research?based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.